# Final Review

**Purpose:** Log the paper's final state after all revisions
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-28T15:42:25.803960
**Response ID:** resp_022b2aa085ab006400697a1fc8528c81979446dd9b23ddc99d
**Tokens:** 6500 in / 5721 out
**Response SHA256:** c1cd8a257f412d63

---

## Referee Report: “Telehealth Parity Laws and Depression Diagnosis Prevalence: Evidence from Staggered State Adoption” (Jan 28, 2026)

### Summary (what the paper does)
The paper estimates the effect of state telehealth parity laws (private insurance coverage mandates) on **lifetime depression diagnosis prevalence** (BRFSS “ever told you have depression”), using **staggered-adoption DiD** (2011–2019). The headline result is a near-zero/negative, statistically insignificant ATT (Callaway–Sant’Anna): **−0.48 pp (SE 0.35)**.

This is a cleanly stated question and the paper uses a modern staggered-DiD estimator. However, for a top general-interest journal, the current version is not close: the contribution is narrow, the main outcome is poorly matched to the mechanism, the policy treatment is coded too coarsely, inference choices need strengthening, and the writing/structure reads like a short policy note rather than a journal article.

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norms.** The PDF excerpt appears to be **~13 pages total including references** (pp. 1–13 shown), with main text ~10 pages. The requirement you stated is **≥25 pages excluding references/appendix**; the paper is far below that.

### References
- The bibliography contains some core items (Callaway–Sant’Anna; Goodman-Bacon; de Chaisemartin–D’Haultfoeuille; Barnett et al.; Mehrotra et al.).
- But it is **not adequate** for (i) modern DiD practice (missing key references), (ii) telehealth policy evaluation, and (iii) mental health access/diagnosis measurement.

### Prose vs bullets
- **Major issue:** Several substantive sections rely on bullet lists rather than paragraph development:
  - **Section 2.3 “Limitations of Parity Laws”** (p. 4) is bullet-pointed.
  - **Section 6 “Discussion”** (pp. 9–10) is largely structured as short subsections that read like memo bullets.
- Bullet points are fine for variable definitions/robustness checklists, but here they substitute for argumentation.

### Section depth (3+ substantive paragraphs each)
- **Introduction (Section 1, pp. 1–2):** roughly 3–5 paragraphs → OK.
- **Institutional background (Section 2, pp. 2–4):** thin; much is bullets; not 3+ substantive paragraphs per subsection.
- **Data (Section 3, pp. 4–5):** short; missing key details (weighting, aggregation, measurement).
- **Results (Section 5, pp. 6–9):** somewhat fuller, but still brief by top-journal standards.
- **Discussion/Conclusion (Sections 6–7, pp. 9–10):** not deep; largely asserted mechanisms.

### Figures
- Figure 1 (event study) appears to have axes and CIs and visible data (p. 7–8). That’s good.
- But: it’s not publication-quality yet (font/labels look like default output; unclear data density; needs clearer notes and perhaps pooled pretrend test).

### Tables
- Tables 1–5 contain real numbers (no placeholders). Good.
- However, Table 4 cohort “significance” flags with **cohorts of size 1** are not credible as presented (see inference comments below).

**Bottom line on format:** Underlength + memo-like prose/structure would lead to desk rejection at AER/QJE/JPE/ReStud/Ecta/AEJ:EP.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **Pass:** Main coefficients report SEs in parentheses (Table 3, Table 5). Cohort SEs shown (Table 4).

### (b) Significance testing
- **Pass:** p-values and “significance” indicators are provided.

### (c) Confidence intervals
- **Pass:** Table 3 includes 95% CIs; Figure 1 includes pointwise 95% bands.

### (d) Sample sizes
- **Mostly pass:** The paper reports N=458 state-years and the state counts.  
- **But:** If you estimate anything beyond a single ATT (group-time ATTs, event study), top journals expect more explicit reporting of **effective sample sizes by event time / cohort**, and attrition/missingness discussion.

### (e) DiD with staggered adoption
- **Pass in principle:** Uses Callaway & Sant’Anna with not-yet-treated controls; TWFE is presented only “for comparison.”
- **But:** You need to be more explicit on:
  - exact implementation (e.g., `att_gt` settings, anticipation window, choice of control group “notyettreated” vs “nevertreated”),
  - whether you used **state-year means** or microdata,
  - whether you included covariates (doubly robust estimator is mentioned but not specified).

### Inference concerns (this is where it is not yet top-journal credible)
Even though you report SEs, your inference is not yet convincing at “top journal” standard:

1. **Few clusters (51) + serial correlation:** Clustering at the state level is standard, but with 51 clusters and highly persistent outcomes, reviewers will expect:
   - **wild cluster bootstrap** p-values (or randomization/permutation inference),
   - sensitivity to alternative correlation structures,
   - explicit acknowledgement of Bertrand–Duflo–Mullainathan (2004) issues.

2. **Cohorts of size 1 (Table 4):** Declaring cohort effects “significant” when a cohort has **one treated state** (2017 cohort: 1 state; 2019 cohort: 1 state) is not persuasive. With one treated unit, the estimate is effectively a treated-state-specific deviation from a constructed control trend; uncertainty is not well-captured by conventional clustered bootstraps. At minimum:
   - report those as **case studies** rather than “cohort estimates,” or
   - aggregate late adopters, or
   - use randomization inference tailored to few treated units.

3. **Multiple testing / event-study inference:** With multiple post-treatment coefficients, pointwise 95% CIs are not enough. You should report:
   - a **joint test** of pre-trends (all leads = 0),
   - and consider **simultaneous confidence bands** (or at least discuss multiple comparisons).

**Methodology verdict:** The paper is not “unpublishable” on inference grounds (it clears the minimum bar), but it is *not* yet at a level that would survive top-field refereeing without stronger inference and transparency.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
The core design—staggered DiD around parity-law adoption—is standard. The paper discusses parallel trends and shows an event study (Figure 1). That said, the identification story is currently not compelling for causal interpretation because of three central problems:

1. **Outcome is a stock, not a flow (major threat to interpretability).**  
   Lifetime “ever diagnosed with depression” evolves slowly and reflects:
   - cumulative diagnoses over decades,
   - cohort composition and migration,
   - changing screening norms,
   - survey reporting behavior.
   
   Even if parity laws increased tele-mental-health visits, the marginal effect on *lifetime diagnosis prevalence from 2011–2019* could be mechanically tiny. This makes null results hard to interpret: is it “no access effect,” or “wrong outcome”?

2. **Treatment is coded too coarsely relative to the mechanism.**
   - Parity laws differ (coverage vs payment parity; modality restrictions; originating-site rules; provider types; mental health carve-outs).
   - Coding “treated if in effect for the full calendar year” introduces **timing mismeasurement** and attenuates effects.
   - Without distinguishing payment parity (stronger) from coverage parity (weaker), you risk pooling heterogeneous treatments into noise.

3. **Concurrent policies and secular trends not addressed.**
   Between 2011–2019, states experienced major confounders correlated with telehealth policy adoption:
   - **ACA Medicaid expansions (2014+)** and related outreach,
   - state mental health parity enforcement and network adequacy actions,
   - opioid-crisis responses,
   - broadband expansion and telehealth grant programs,
   - changes in provider licensing and scope-of-practice.
   
   A top-journal DiD paper needs a more serious accounting of these.

### Parallel trends / placebo tests
- Event study pre-trends are described as “small and insignificant,” but that is not enough. You need:
  - a **joint pretrend test**, and
  - plots/tables showing **raw outcome trends** by cohort and controls.
- Placebos:
  - Use outcomes unlikely to be affected (e.g., arthritis diagnosis, height—if available; or other chronic diagnosis measures).
  - Use “fake adoption years” in never-treated states (randomization inference / permutation).

### Do conclusions follow?
The conclusion states “telehealth parity laws alone may have had limited effects on access.” Given the outcome limitations, the most defensible conclusion is narrower:
- “We detect no effect on *lifetime depression diagnosis prevalence* in BRFSS.”  
The stronger “access” language overreaches without direct utilization/treatment measures.

### Limitations discussion
You do list limitations (ERISA, adoption barriers, measurement), but mostly as bullets and without quantification. A top journal will expect sharper quantification (e.g., the share of privately insured in fully insured plans by state; heterogeneity by ERISA exposure).

---

# 4. LITERATURE (Missing references + BibTeX)

## Methodology (staggered DiD)
You cite Callaway–Sant’Anna, Goodman-Bacon, and de Chaisemartin–D’Haultfoeuille. Missing several now-standard references that referees will expect:

1. **Sun & Abraham (2021)** (event-study under staggered adoption; negative weights critique and solution).
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2. **Borusyak, Jaravel & Spiess (2021)** (imputation / “did-imputation” approach).
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {American Economic Review Papers and Proceedings},
  year    = {2021},
  volume  = {111},
  pages   = {315--322}
}
```

3. **Roth et al. (2023)** (practical guidance and diagnostics for DiD).
```bibtex
@article{RothSantAnnaBilandzicEtAl2023,
  author  = {Roth, Jonathan and Sant'Anna, Pedro H. C. and Bilinski, Alyssa and Poe, John},
  title   = {What's Trending in Difference-in-Differences? A Synthesis of the Recent Econometrics Literature},
  journal = {Journal of Econometrics},
  year    = {2023},
  volume  = {235},
  number  = {2},
  pages   = {2218--2244}
}
```

4. **Bertrand, Duflo & Mullainathan (2004)** (serial correlation in DiD).
```bibtex
@article{BertrandDufloMullainathan2004,
  author  = {Bertrand, Marianne and Duflo, Esther and Mullainathan, Sendhil},
  title   = {How Much Should We Trust Differences-in-Differences Estimates?},
  journal = {Quarterly Journal of Economics},
  year    = {2004},
  volume  = {119},
  number  = {1},
  pages   = {249--275}
}
```

5. (Optional but often expected) **Sant’Anna & Zhao (2020)** (doubly robust DiD foundations).
```bibtex
@article{SantAnnaZhao2020,
  author  = {Sant'Anna, Pedro H. C. and Zhao, Jun},
  title   = {Doubly Robust Difference-in-Differences Estimators},
  journal = {Journal of Econometrics},
  year    = {2020},
  volume  = {219},
  number  = {1},
  pages   = {101--122}
}
```

## Telehealth policy and utilization literature
Right now, the paper leans on a few descriptive telemedicine papers. A policy-evaluation paper needs engagement with:
- **payment parity vs coverage parity** impacts,
- utilization and spending substitution/addition,
- mental health telehealth specifically pre-COVID.

At minimum, consider adding and discussing:

- **Ashwood et al. (2017, Health Affairs)** on telehealth and spending/utilization (commercial).
```bibtex
@article{AshwoodMehrotraCowieEtAl2017,
  author  = {Ashwood, J. Scott and Mehrotra, Ateev and Cowie, Benjamin and Uscher-Pines, Lori},
  title   = {Direct-To-Consumer Telehealth May Increase Access To Care But Does Not Decrease Spending},
  journal = {Health Affairs},
  year    = {2017},
  volume  = {36},
  number  = {3},
  pages   = {485--491}
}
```

- **Uscher-Pines & Mehrotra** (multiple papers) on telehealth adoption barriers and regulation; pick one or two central references relevant to pre-COVID parity mandates.

- Evidence on **mental health telehealth growth** and substitution patterns pre-COVID beyond Mehrotra et al. (2017); several Health Affairs / JAMA Network Open papers exist and should be cited and contrasted.

## Measurement / depression diagnosis
Given you use BRFSS “ever diagnosed,” you should cite work on:
- survey-based mental health measurement,
- diagnosis vs symptoms,
- changes in screening and reporting over time.

Even a small set of citations would help position what “lifetime diagnosis prevalence” captures.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets (fails top-journal expectations)
- Sections 2.3 and much of Section 6 rely on bullet structure rather than persuasive prose (pp. 4, 9–10). For AER/QJE/JPE/ReStud/Ecta/AEJ:EP, this reads as **a research memo**, not an article.

### Narrative flow
- The introduction (pp. 1–2) states the question clearly, but it does not “hook” with a motivating fact that directly supports the empirical approach (e.g., pre-period utilization levels, why parity laws plausibly bind, why depression diagnosis is the right margin).
- The paper’s arc is currently: policy exists → DiD → null result → reasons. That is not enough. A top journal needs either:
  - a sharper conceptual framework (why parity should/shouldn’t move diagnosis), or
  - richer evidence that the mechanism did/didn’t operate (utilization, provider entry, claims).

### Accessibility and magnitudes
- The magnitude discussion is thin. A −0.48 pp effect relative to a mean of 19% is ~−2.5% relative—small. But without a first-stage (telehealth use) and without a flow outcome, readers cannot interpret what “small” means.
- The “MDE” calculation is helpful, but should be placed in a proper power section with assumptions and/or simulation.

### Tables/figures quality
- Needs journal styling: clearer notes, consistent significant digits, and more self-contained explanations (e.g., what exactly is the event-study normalization period; how are weights used).

---

# 6. CONSTRUCTIVE SUGGESTIONS (to make it publishable somewhere strong)

## A. Fix the outcome/measurement problem (highest priority)
1. **Use a flow outcome** more tightly linked to access:
   - past-year mental health treatment (if available in BRFSS modules),
   - # poor mental health days (BRFSS “MENTHLTH”) as a symptom measure,
   - antidepressant use (not in BRFSS, but in claims/surveys),
   - outpatient mental health visits, psychotherapy initiation (claims).
2. If staying with “ever diagnosed,” explicitly model it as a stock:
   - show expected mechanical attenuation,
   - estimate impacts on *new diagnoses* if derivable (e.g., among young cohorts, or using age-restricted samples where “ever” is closer to recent).

## B. Strengthen treatment measurement
1. Separate **coverage parity vs payment parity** and key scope dimensions (audio-only, rural restrictions, etc.).
2. Code **effective dates** more precisely (month/quarter), and run sensitivity:
   - treat adoption year as partial exposure,
   - drop ambiguous implementation years.
3. Show a table (appendix) listing **each state’s adoption date, law type, and sources**.

## C. Show the mechanism (“first stage”)
A null reduced form is not informative without knowing whether parity laws increased telehealth use. Add:
- claims-based telehealth utilization (MarketScan, FAIR Health, Medicare for older adults, or state APCDs where available),
- or at least external telehealth adoption measures (provider telehealth offerings, broadband, etc.).
Even a descriptive first-stage (“telehealth visits rose by X% after parity”) would dramatically improve interpretability.

## D. Address confounding policies
At minimum:
- control for **Medicaid expansion** and interact with insurance composition,
- include controls for broadband penetration, psychiatrist supply, opioid mortality, unemployment.
Better:
- triple-difference by **ERISA exposure** (share self-insured) or by **privately insured fully-insured share** (parity should bite there).

## E. Inference upgrades
- Report **wild cluster bootstrap** p-values for the main ATT and key event-time estimates.
- Provide a **joint pre-trends test** and (ideally) simultaneous bands.
- Re-think Table 4 “cohort effects” with n=1 cohorts; either pool cohorts or present as state-specific case studies.

## F. Writing and structure overhaul
- Convert bullet-point sections (2.3, 6.x) into full paragraphs with citations and logic.
- Add a short conceptual framework: why parity affects access; what margins move (provider supply, patient demand, prices), and why diagnosis is/waswo is not the right outcome.
- Expand to a full-length paper: richer institutional detail, robustness, heterogeneity, and mechanism.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Clear policy question and clean pre-COVID window (2011–2019).
- Uses an appropriate modern staggered-DiD estimator (Callaway–Sant’Anna) rather than relying on TWFE.
- Transparent reporting of the main estimate with SE and CI.

### Critical weaknesses
1. **The main outcome is poorly matched to the mechanism** (lifetime diagnosis is a slow-moving stock; null results are hard to interpret).
2. **Treatment is under-measured** (heterogeneous parity laws collapsed into a single indicator; timing misclassification).
3. **Insufficient engagement with confounders and mechanism** (no first stage; minimal policy controls).
4. **Underlength and writing format not suitable for a top general-interest journal** (memo-like bullets; limited section depth).
5. **Inference presentation is not yet credible for small-n cohorts and multiple testing** (Table 4; event study).

### What would change my view
If the authors (i) move to utilization/treatment or new-diagnosis outcomes, (ii) show a telehealth-utilization first stage, (iii) refine parity law measurement (payment vs coverage), and (iv) substantially expand the paper with stronger inference and confounder discussion, the project could become publishable—likely first at a strong field journal, and only potentially at AEJ:EP/general-interest if the mechanism and contribution become broader.

DECISION: REJECT AND RESUBMIT